Viking Therapeutics (VKTX) Corporate presentation summary

Strategic focus and pipeline

• Advancing novel therapeutics for metabolic and endocrine diseases, with multiple clinical programs showing strong efficacy data.

• Lead asset VK2735, a dual GLP-1/GIP agonist, is in Phase 3 for obesity, with both injectable and oral formulations in late-stage development.

• Additional programs include VK3019 (amylin agonist for obesity), VK2809 (TRβ agonist for MASH), and VK0214 (TRβ agonist for X-ALD), all progressing through clinical phases.

VK2735 clinical results and efficacy

• VK2735 demonstrated up to 14.7% mean weight loss after 13 weeks in Phase 2 studies, with no plateau observed, indicating potential for further reduction.

• Both oral and subcutaneous formulations showed dose-dependent, progressive weight loss, with efficacy maintained weeks after last dose.

• Exploratory maintenance cohorts suggest lower maintenance doses can sustain or extend weight loss.

Safety and tolerability

• Across studies, 92–99% of adverse events were mild to moderate, with GI-related events (nausea, vomiting, diarrhea, constipation) most common and generally transient.

• GI adverse events were most frequent early in treatment and subsided over time; titration schedules may further improve tolerability.